Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-08-15

Clinical Trial Update: An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options [Phase 3]

View source ↗

Summary

Phase 3 expanded-access trial of spesolimab in Japan for flare-ups of generalized pustular psoriasis, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SPESOLIMAB (BI655130)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Generalized Pustular Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2024-08-15